Episode Summary
In this episode of TOGA’s Conversations in Lung Cancer Research, host A/Prof Steven Kao, Medical Oncologist at Chris O’Brien Lifehouse, is joined by A/Prof Venessa Chin, Medical Oncologist at St Vincent’s Hospital and Researcher at the Garvan Institute of Medical Research, and Dr Ben Kong, Medical Oncologist at Prince of Wales Hospital. Together, they explore the clinical features of ROS1-positive non-small cell lung cancer, the evolving diagnostic and treatment landscape in Australia, and how the recent PBS listing of repotrectinib is influencing first-line treatment decisions. The discussion also covers CNS disease, treatment sequencing, resistance mechanisms, and emerging therapies that may further improve outcomes for patients.
Sponsors
This podcast was proudly sponsored by Bristol Myers Squibb. All development and editorial decisions were made independently by the speakers.
Speakers
- A/Prof Steven Kao, Medical Oncologist, Chris O’Brien Lifehouse
- A/Prof Venessa Chin, Medical Oncologist, St Vincent’s Hospital, Researcher, Garvan Institute of Medical Research
- Dr Ben Kong, Medical Oncologist, Prince of Wales Hospital
